Clinical trials: Esrd
Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.
- Trial name
- VENOS-2 (NCT06712251)
- Testing
- Velocity pAVF System
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Venova Medical
Primary Hyperoxaluria Type 1, End Stage Renal Disease
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
- Trial name
- PHYOX7 (NCT04580420)
- Testing
- DCR-PHXC
- Where
- 18 sites in United States, France and 8 more
- Volunteers
- 28 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Dyslipidemia
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers
To analyze efficacy of fluvastatin on patients with chronic renal disease by analyzing certain inflammatory markers. In addition, tolerability and safety will also be evaluated in a Spanish population.
- Trial name
- NCT00171262
- Testing
- Fluvastatin
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Novartis
Healthy
Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension
To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with varying degrees of renal impairment
- Trial name
- NCT00637403
- Testing
- Megestrol acetate concentrated suspension 125 mg/mL
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Fibrosis, Renal Impairment
Safety of Gadovist in Renally Impaired Patients
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Gadovist, will be asked to participate.
- Trial name
- GRIP (NCT00828737)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 70 sites in Australia, Austria and 8 more
- Volunteers
- 927 people
- Sponsor
- Bayer
Chronic Kidney Disease, Stage 5, Secondary Hyperparathyroidism
A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
The purpose of this study is to evaluate the effects of Zemplar® Injection and Hectorol® Injection on intestinal calcium absorption in Chronic Kidney Disease Stage 5 subjects on hemodialysis.
- Trial name
- NCT00257920
- Testing
- Zemplar® injection, Hectorol® injection
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Abbott
Contrast Induced Acute Kidney Injury
Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI
This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary…
- Trial name
- NCT05758896
- Testing
- Isuzinaxib (APX-115)
- Where
- 14 sites in United States, South Korea
- Volunteers
- 218 people
- Sponsor
- Aptabio Therapeutics, Inc.
Diabetic Peripheral Neuropathic Pain, Post-herpetic Neuralgia
DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
Investigate the safety and efficacy of DS-5565 in Japanese subjects with Diabetic Peripheral Neuropathic Pain (DPNP) with renal impairment or Post-Herpetic Neuralgia (PHN) with renal impairment.
- Trial name
- NCT02607280
- Testing
- DS-5565
- Where
- Japan
- Volunteers
- 35 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Kidney Diseases, Renal Insufficiency
Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia
This is a randomized, dose-ranging, efficacy and tolerability study in chronic kidney disease patients with hyperphosphatemia on hemodialysis. Patient participation in the study is approximately 10 weeks in duration.
- Trial name
- NCT00358046
- Testing
- ILY101
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ilypsa
Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis
- Trial name
- SBR759 (NCT00704483)
- Testing
- SBR759, Sevelamer HCl
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
End-Stage Renal Disease Requiring Haemodialysis
Effect of Amplifi Vein Dilation System Treatment on Radiocephalic AVF Maturation-3
This multi-phase clinical study evaluated the safety and performance of the Amplifi Vein Dilation System (Amplifi System) in subjects requiring arteriovenous fistula (AVF) creation.
- Trial name
- Amplifi FIH (NCT07058610)
- Testing
- Amplifi Vein Dilation System
- Where
- Paraguay
- Volunteers
- 19 people
- Sponsor
- Amplifi Vascular, Inc.
End Stage Kidney Disease, End Stage Renal Disease
Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.
- Conditions
- End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
- Trial name
- COMPARE (NCT04912024)
- Testing
- Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Outset Medical
Kidney Transplantation, Transplantation
Pre-transplant Assessment of Tacrolimus Blood Level Concentration, as a Predictor of Tacrolimus Dose Requirements After Kidney Transplantation
The purpose of this study is to evaluate two groups of kidney transplant recipients, to determine the proportion of patients that achieve therapeutic blood concentrations of tacrolimus by Day 3 after transplantation.
- Trial name
- NCT00297310
- Testing
- tacrolimus
- Volunteers
- 89 people
- Sponsor
- Janssen-Cilag Pty Ltd
Renal Impairment
Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of single subcutaneous dose of AZD6234 with end stage renal disease, severe, and possibly moderate and mild renal impairment in comparison to a matched…
- Trial name
- NCT06845813
- Testing
- AZD6234
- Where
- 3 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
End Stage Renal Disease
New Needle for Two-Needle Hemodialysis
Our preliminary studies have demonstrated that an innovative new design of the hemodialysis venous needle (the needle that returns the cleaned blood from the hemodialysis filter to the patient) with three jets is superior to the…
- Trial name
- BME-1 (NCT01416896)
- Testing
- Hemodialysis using the standard venous needle, Hemodialysis using a new venous needle, the "BME needle"
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Biomedical Enterprises Inc
Chronic Kidney Diseases
Late Feasibility Study to Evaluate Safety and Efficacy of AWAK PD Device in Subjects With ESKD.
The goal of this late feasibility clinical trial is to evaluate the safety and effectiveness of the Automated Wearable Artificial Kidney (AWAK) peritoneal dialysis (PD) device in subjects with end-stage kidney disease.
- Trial name
- NCT05827588
- Testing
- AWAK PD
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- AWAK Technologies Pte Ltd
IgA Nephropathy, Immunoglobulin A Nephropathy
A Study of Zigakibart in Adults With IgA Nephropathy
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
- Trial name
- NCT05852938
- Testing
- BION-1301
- Where
- 200 sites in United States, Argentina and 21 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Soft Tissue Infections
Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections
This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of daptomycin relative to comparator in the…
- Trial name
- NCT00102947
- Testing
- daptomycin (up to 14 days)
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cardiac Rhythm Disorders, Urological Disorders
Product Surveillance Registry
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products.
- Conditions
- Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
- Trial name
- PSR (NCT01524276)
- Where
- 402 sites in United States, Argentina and 39 more
- Volunteers
- 100,000 people
- Sponsor
- Medtronic
Renal Impairment, Healthy
A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
The purpose of this study is to evaluate the pharmacokinetics of a single dose of intranasally administered esketamine in participants with impaired renal function when compared to participants with normal renal function.
- Trial name
- NCT02606084
- Testing
- Esketamine
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.